Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development

Juan J. Gu; Anil Singh; Kai Xue; Cory Mavis; Matthew Barth; Vivek Yanamadala; Peter Lenz; Michael Grau; Georg Lenz; Myron S. Czuczman; Francisco J. Hernandez-Ilizaliturri

doi:10.18632/oncotarget.23425

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development

Juan J. Gu, Anil Singh, Kai Xue, Cory Mavis, Matthew Barth, Vivek Yanamadala, Peter Lenz, Michael Grau, Georg Lenz, Myron S. Czuczman and Francisco J. Hernandez-Ilizaliturri _

PDF | HTML | How to cite

Oncotarget. 2018; 9:4020-4033. https://doi.org/10.18632/oncotarget.23425

Metrics: PDF 1815 views | HTML 2294 views | ?

Abstract

Juan J. Gu1, Anil Singh1, Kai Xue4, Cory Mavis1, Matthew Barth3, Vivek Yanamadala2, Peter Lenz5, Michael Grau6,7, Georg Lenz6,7, Myron S. Czuczman8 and Francisco J. Hernandez-Ilizaliturri1,2

1Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA

2Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York, USA

3Department of Pediatric Oncology, Roswell Park Cancer Institute, Buffalo, New York, USA

4Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China

5Department of Physics, Philipps-University, Marburg, Germany

6Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany

7Cluster of Excellence EXC 1003, Cells in Motion, Münster, Germany

8Celgene, Summit, New Jersey, USA

Correspondence to:

Francisco J. Hernandez-Ilizaliturri, email: [email protected]

Keywords: hexokinase II; rituximab-chemotherapy resistance; lymphoma; glucose metabolism

Received: May 10, 2017 Accepted: November 26, 2017 Published: December 19, 2017

ABSTRACT

In order to identify cellular pathways associated with therapy-resistant aggressive lymphoma, we generated rituximab-resistant cell lines (RRCL) and found that the acquirement of rituximab resistance was associated with a deregulation in glucose metabolism and an increase in the apoptotic threshold leading to chemotherapy resistance. Hexokinase II (HKII), the predominant isoform overexpressed in cancer cells, has dual functions of promoting glycolysis as well as inhibiting mitochondrial-mediated apoptosis. We found that RRCL demonstrated higher HKII levels. Targeting HKII resulted in decreased mitochondrial membrane potential, ATP production, cell viability; and re-sensitization to chemotherapy agents. Analyzed gene expression profiling data from diffuse large B-cell lymphoma patients, high-HKII levels were associated with a shorter progression free survival (PFS) and/or overall survival (OS). Our data suggest that over-expression of HKII is associated with resistance to rituximab and chemotherapy agents in aggressive lymphoma and identifies this enzyme isoform as a potential therapeutic target.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23425

Publication Alerts

Research Papers:

Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development

Abstract